1
|
Valldeoriola F, Grandas F, Arbelo JM, Blázquez Estrada M, Calopa Garriga M, Campos-Arillo VM, Garcia Ruiz PJ, Gómez Esteban JC, Leiva Santana C, Martínez Castrillo JC, Mir P, Salvador Aliaga A, Vivancos Matellano F, Yáñez Baña RM. Spanish expert consensus on the use of safinamide in Parkinson's disease. Neurologia 2018; 36:S0213-4853(18)30172-5. [PMID: 30072274 DOI: 10.1016/j.nrl.2018.04.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 04/12/2018] [Accepted: 04/18/2018] [Indexed: 01/17/2023] Open
Abstract
Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. Due to the recent incorporation of safinamide into routine clinical practice, no post-authorisation phase IV studies on the safety of safinamide have been conducted to date. This study provides clinical management guidelines for safinamide based on the opinion of a group of experts in movement disorders. This project was developed in 2 phases: 16 local meetings in phase 1 and a national meeting in phase 2. The meetings followed a pre-established agenda. The present clinical practice guidelines are based on the main conclusions reached during the national meeting. The group concluded that safinamide is effective in reducing motor and non-motor fluctuations. PD patients with mild-to-moderate fluctuations benefit most from treatment, although the drug may also improve the clinical status of patients with advanced PD. The dose of other dopaminergic drugs may be reduced after introducing safinamide, which would contribute to reducing such adverse reactions as impulse control disorder. At doses higher than those usually prescribed, safinamide may also improve dyskinesia. The experts agreed that safinamide is well tolerated and causes few adverse reactions when compared with placebo.
Collapse
Affiliation(s)
- F Valldeoriola
- Institut de Neurociències, Servei de Neurologia, Unitat de Trastorns del Moviment, Hospital Clínic de Barcelona, Barcelona, España.
| | - F Grandas
- Unidad de Trastornos del Movimiento, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - J M Arbelo
- Hospital Insular Universitario de Gran Canaria, Telde (Las Palmas de Gran Canaria), España
| | - M Blázquez Estrada
- Servicio de Neurología, Hospital Universitario Central de Asturias, Oviedo (Asturias), España
| | - M Calopa Garriga
- Unidad Trastornos de Movimiento, Servicio de Neurología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), España
| | - V M Campos-Arillo
- Hospital Vithas Xanit Internacional Benalmádena, Benalmádena (Málaga), España
| | - P J Garcia Ruiz
- Servicio de Neurología, Fundación Jiménez Díaz; Universidad Autónoma de Madrid, Madrid, España
| | - J C Gómez Esteban
- Área de Enfermedades Neurodegenerativas, Instituto de Investigación Biocruces, Hospital Universitario de Cruces, Barakaldo (Vizcaya), España
| | - C Leiva Santana
- Servicio de Neurología, Hospital General de Alicante, Alicante, España
| | | | - P Mir
- Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, España
| | - A Salvador Aliaga
- Servicio de Neurología, Hospital Clínico Universitario de Valencia, Valencia, España
| | - F Vivancos Matellano
- Unidad de Trastornos del Movimiento, Servicio de Neurología, Hospital Universitario, Madrid, España
| | - R M Yáñez Baña
- Servicio de Neurología, Complejo Hospitalario Universitario de Ourense, Orense, España
| |
Collapse
|